

DEC 16 2005

K053154

## 510(k) Summary

The following safety and effectiveness summary has been prepared pursuant to requirement for 510(k) summaries specified in 21CFR§807.92(a).

### 807.92(a)(1)

#### **Submitter Information**

Carri Graham, Official Correspondent  
7992 Castleway Drive  
Indianapolis, IN 46250  
Phone: (317) 849-1916  
Facsimile: (317) 577-9070

Contact Person: Carri Graham

Date: November 10, 2005

### 807.92(a)(2)

Trade Name: MyLab15/20 – Just3D and Just 4D Ultrasound System

Common Name: Ultrasound Imaging System

Classification Name(s): Ultrasonic pulsed echo imaging system 892.1560  
Ultrasonic pulsed Doppler imaging system 832.1550

Classification Number: 90IYO  
90IYN

### 807.92(a)(3)

#### **Predicate Device(s)**

K014168	Technos	Esaote, S.p.A.
K043588	MyLab15/20 Ultrasound System	Pie Medical
K043455	8000Live	Medison
K040060	G50	Siemens

Additional Substantial Equivalence Information is provided in the following substantial Equivalence Comparison Table.

**807.92(a)(4)**

**Device Description**

The MyLab15/20 is a compact console ultrasound system used to perform general diagnostic ultrasound studies. Its primary modes of operation are: B-Mode, M-Mode, PW Doppler and Color Flow Mapping and Tissue Enhancement Imaging (TEI). MyLab15/20 is able to produce real time 2D images and 3D images (in manual mode) with all probes. The system, in combination with the probe BC432P, offers the possibility to also produce automatic 3D and real time 4D images

**807.92(a)(5)**

**Intended Use(s)**

Esaote's MyLab15/MyLab20 is a compact console ultrasound system intended to be used by a physician to perform general diagnostic ultrasound studies including Fetal, Abdominal, Pediatric, Small organ, Neonatal Cephalic, Cardiac, Transrectal, Transvaginal, Peripheral Vascular, Musculoskeletal (Conventional and Superficial).

**Comparison Chart for Substantial Equivalence**

General Characteristics	Esaote MyLab15/20	Medison 8000Live (k043455)	Siemens G50 (k040060)
<i>Applications</i>			
Fetal	Yes	Yes	Yes
Abdominal	Yes	Yes	Yes
Pediatric	Yes	Yes	Yes
Small Organ	Yes	Yes	Yes
Neonatal Cephalic	Yes	Yes	Yes
Cardiac	Yes	Yes	Yes
Transrectal	Yes	Yes	Yes
Transvaginal	Yes	Yes	Yes
Peripheral Vascular	Yes	Yes	Yes
Musculo-skeletal (Conventional and superficial)	Yes	Yes	Yes

General Characteristics	Esaote MyLab15/20	Medison 8000Live (k043455)	Siemens G50 (k040060)
<b>Transducer Type</b>			
<b>Linear</b>	Yes	Yes	Yes
<b>Convex</b>	Yes	Yes	Yes
<b>Phased array</b>	No	Yes	Yes
<b>2D Freq MHz</b>	2.7 – 15	1 - 20	2 - 12
<b>Multifrequency</b>	Yes	Yes	Yes
<b>Special probes</b>	<ul style="list-style-type: none"> <li>• Endocavity probe</li> <li>• Mechanically Driven 3D Convex Array</li> </ul>	<ul style="list-style-type: none"> <li>• Endocavity probe</li> <li>• Mechanically Driven 3D Convex Array</li> <li>• CW Doppler Probe</li> </ul>	<ul style="list-style-type: none"> <li>• Endocavity probe</li> <li>• Mechanically Driven 3D Convex Array</li> <li>• Laparoscopic</li> <li>• CW Doppler Probe</li> </ul>
<b>Biopsy attachments</b>			
<b>Convex</b>	Yes	Yes	Yes
<b>Linear</b>	Yes	Yes	Yes
<b>Imaging modes</b>			
<b>Real Time 2D</b>	Yes	Yes	Yes
<b>M-mode</b>	Yes	Yes	Yes
<b>PW Doppler</b>	Yes	Yes	Yes
<b>CW Doppler</b>	No	Yes	Yes
<b>CFM Doppler</b>	Yes	Yes	Yes
<b>Amplitude Doppler</b>	Yes	Yes	Yes
<b>Triplex</b>	Yes	Yes	Yes
<b>3D/4D</b>	Yes	Yes	Yes
<b>Monitor size (inches)</b>	<ul style="list-style-type: none"> <li>• 15" CRT monitor</li> <li>• 15" LCD</li> </ul>	15" Color VGA CRT Monitor	15" CRT monitor
<b>ECG</b>	Optional	Optional	Optional
<b>Digital archival capabilities</b>	Yes	Yes	Yes
<b>VCR &amp; Video printers</b>	Yes	Yes	Yes
<b>M&amp;A capabilities</b>	Yes	Yes	Yes
<b>Safety</b>			
<b>Electrical safety</b>	EN60601-1	EN60601-1	EN60601-1



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

DEC 16 2005

Food and Drug Administration  
9200 Corporate Boulevard  
Rockville MD 20850

Pie Medical  
% Carri Graham  
The Anson Group  
7992 Castleway Drive  
INDIANAPOLIS IN 46250

Re: K053154  
Trade Name: MyLab15/MyLab20 Ultrasound Imaging System  
(with 3D/4D Imaging Option)  
Regulation Number: 21 CFR 892.1550/1560/1570  
Regulation Name: Ultrasonic pulsed Doppler imaging system; Ultrasonic pulsed echo  
imaging system; Diagnostic ultrasonic transducer.  
Regulatory Class: II  
Product Code: IYN; IYO; ITX  
Dated: November 10, 2005  
Received: November 15, 2005

Dear Ms. Graham:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

This determination of substantial equivalence applies to the following transducers intended for use with the MyLab15/MyLab20 Ultrasound Imaging System, as described in your premarket notification:

Transducer Model Numbers

LA523; LA424; CA421P; CA421; CA621; BC432P; EC123; E8-5 R10

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This determination of substantial equivalence is granted on the condition that prior to shipping the first device, you submit a postclearance special report. This report should contain complete information, including acoustic output measurements based on production line devices, requested in Appendix G, (enclosed) of the Center's September 30, 1997 "Information for Manufacturers Seeking Marketing Clearance of Diagnostic Ultrasound Systems and Transducers." If the special report is incomplete or contains unacceptable values (e.g., acoustic output greater than approved levels), then the 510(k) clearance may not apply to the production units which as a result may be considered adulterated or misbranded.

The special report should reference the manufacturer's 510(k) number. It should be clearly and prominently marked "ADD-TO-FILE" and should be submitted in duplicate to:


Food and Drug Administration  
Center for Devices and Radiological Health  
Document Mail Center (HFZ-401)  
9200 Corporate Boulevard  
Rockville, Maryland 20850

This letter will allow you to begin marketing your device as described in your premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus permits your device to proceed to market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (240) 276-0120. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address <http://www.fda.gov/cdrh/industry/support/index.html>

If you have any questions regarding the content of this letter, please contact Rodrigo C. Perez at (301) 594-1212.

Sincerely yours,



Nancy C. Brogdon  
Director, Division of Reproductive,  
Abdominal and Radiological Devices  
Office of Device Evaluation  
Center for Devices and  
Radiological Health

### 4.3 Indications for Use

The following table provides the intended clinical use for the MyLab15/20:

Clinical Application	Mode of Operation									
	A	B	M	PWD	CWD	Color Doppler	Amplitude Doppler	Color Velocity Imaging	Combined (specify)	Other (specify)
Ophthalmic										
Fetal		P	P	P		P	P		P [2]	P[3], N[4], N[5]
Abdominal		P	P	P		P	P		P [2]	P[3], N[4], N[5]
Intraoperative (specify)										
Intraoperative Neurological										
Pediatric		P	P	P		P	P		P [2]	P[3], N[4], N[5]
Small Organ (specify) [1]		P	P	P		P	P		P [2]	P[3], N[4]
Neonatal Cephalic		P	P	P		P	P		P [2]	P[3], N[4]
Adult Cephalic										
Cardiac		P	P	P		P	P		P [2]	P[3]
Transesophageal										
Transrectal		P	P	P		P	P		P [2]	P[3], N[4]
Transvaginal		P	P	P		P	P		P [2]	P[3], N[4]
Transurethral										
Intravascular										
Peripheral Vascular		P	P	P		P	P		P [2]	P[3], N[4]
Laparoscopic										
Musculo-skeletal Conventional		P	P	P		P	P		P [2]	P[3], N[4]
Musculo-skeletal Superficial		P	P	P		P	P		P [2]	P[3], N[4]
Other (specify)										

N=new indication; P=previously cleared by FDA; E= added under Appendix E

Additional Comments:

- [1] Small organs include Thyroid, Breast and Testicles.
- [2] Applicable combined modes: B+M+PW+ CFM+Amplitude Doppler
- [3] Tissue Enhancement Imaging (TEI)
- [4] 3D Imaging
- [5] 4D Imaging

Prescription Use ☒

*Nancy C Gordon*  
 (Division Sign-Off)  
 Division of Reproductive, Abdominal,  
 and Radiological Devices  
 510(k) number K053154

The following tables provide the intended clinical use for the MyLab15/20 probes in combination with the system:

Transducer: LA523

Clinical Application	Mode of Operation									
	A	B	M	PWD	CWD	Color Doppler	Amplitude Doppler	Color Velocity Imaging	Combined (specify)	Other (specify)
Ophthalmic										
Fetal										
Abdominal		P	P	P		P	P		P[2]	P[3], N[4]
Intraoperative (specify)										
Intraoperative Neurological										
Pediatric		P	P	P		P	P		P[2]	P[3], N[4]
Small Organ (specify) [1]		P	P	P		P	P		P[2]	P[3], N[4]
Neonatal Cephalic		P	P	P		P	P		P[2]	P[3], N[4]
Adult Cephalic										
Cardiac										
Transesophageal										
Transrectal										
Transvaginal										
Transurethral										
Intravascular										
Peripheral Vascular		P	P	P		P	P		P[2]	P[3], N[4]
Laparoscopic										
Musculo-skeletal Conventional		P	P	P		P	P		P[2]	P[3], N[4]
Musculo-skeletal Superficial		P	P	P		P	P		P[2]	P[3], N[4]
Other (specify)										

N=new indication; P=previously cleared by FDA; E= added under Appendix E

Additional Comments:

- [1] Small organs include Thyroid, Breast and Testicles.
- [2] Applicable combined modes: B+M+PW+CW+CFM+Amplitude Doppler
- [3] Tissue Enhancement Imaging (TEI)
- [4] 3D Imaging

Prescription Use: ✓

*Nancy C. Groopman*  
 (Division Sign Off)  
 Division of Reproductive, Abdominal,  
 and Urinary Tract Devices  
 510(k) Number: K 053154



Transducer: LA424

Clinical Application	Mode of Operation									
	A	B	M	PWD	CWD	Color Doppler	Amplitude Doppler	Color Velocity Imaging	Combined (specify)	Other (specify)
Ophthalmic										
Fetal										
Abdominal		N	N	N		N	N		N[2]	N[3], N[4]
Intraoperative (specify)										
Intraoperative Neurological										
Pediatric		N	N	N		N	N		N[2]	N[3], N[4]
Small Organ (specify) [1]		N	N	N		N	N		N[2]	N[3], N[4]
Neonatal Cephalic		N	N	N		N	N		N[2]	N[3], N[4]
Adult Cephalic										
Cardiac										
Transesophageal										
Transrectal										
Transvaginal										
Transurethral										
Intravascular										
Peripheral Vascular		N	N	N		N	N		N[2]	N[3], N[4]
Laparoscopic										
Musculo-skeletal Conventional		N	N	N		N	N		N[2]	N[3], N[4]
Musculo-skeletal Superficial		N	N	N		N	N		N[2]	N[3], N[4]
Other (specify)										

N=new indication; P=previously cleared by FDA; E= added under Appendix E

Additional Comments:

[1] Small organs include Thyroid, Breast and Testicles.

[2] Applicable combined modes: B+M+PW+CW+CFM+Amplitude Doppler

[3] Tissue Enhancement Imaging (TEI)

[4] 3D Imaging

Prescription File ✓

*Nancy C. Proctor*  
(Division Sign-Off)

Division of Reproductive, Abdominal,

Genital and Urinary Devices

Product Code: K053154

Transducer: CA421P

Clinical Application	Mode of Operation									
	A	B	M	PWD	CWD	Color Doppler	Amplitude Doppler	Color Velocity Imaging	Combined (specify)	Other (specify)
Ophthalmic										
Fetal		P	P	P		P	P		P[1]	P[2], N[3]
Abdominal		P	P	P		P	P		P[1]	P[2], N[3]
Intraoperative (specify)										
Intraoperative Neurological										
Pediatric		P	P	P		P	P		P[1]	P[2], N[3]
Small Organ (specify)										
Neonatal Cephalic										
Adult Cephalic										
Cardiac										
Transesophageal										
Transrectal										
Transvaginal										
Transurethral										
Intravascular										
Peripheral Vascular										
Laparoscopic										
Musculo-skeletal Conventional										
Musculo-skeletal Superficial										
Other (specify)										

N=new indication; P=previously cleared by FDA; E= added under Appendix E

Additional Comments:

- [1] Applicable combined modes: B+M+PW+CFM+Amplitude Doppler.
- [2] Tissue Enhancement Imaging (TEI)
- [3] 3D Imaging

*Nancy C Brogan*  
 (Division Sign-Off)  
 Division of Reproductive, Abdominal,  
 and Radiological Devices  
 b10(k) Number K053154

Transducer: CA421

Clinical Application	Mode of Operation									
	A	B	M	PWD	CWD	Color Doppler	Amplitude Doppler	Color Velocity Imaging	Combined (specify)	Other (specify)
Ophthalmic										
Fetal		P	P	P		P	P		P[1]	P[2], N[3]
Abdominal		P	P	P		P	P		P[1]	P[2], N[3]
Intraoperative (specify)										
Intraoperative Neurological										
Pediatric		P	P	P		P	P		P[1]	P[2], N[3]
Small Organ (specify)										
Neonatal Cephalic										
Adult Cephalic										
Cardiac										
Transesophageal										
Transrectal										
Transvaginal										
Transurethral										
Intravascular										
Peripheral Vascular										
Laparoscopic										
Musculo-skeletal Conventional										
Musculo-skeletal Superficial										
Other (specify)										

N=new indication; P=previously cleared by FDA; E= added under Appendix E

Additional Comments:

[1] Applicable combined modes: B+M+PW+CFM+Amplitude Doppler.

[2] Tissue Enhancement Imaging (TEI)

[3] 3D Imaging

Nancy Brogdon  
(Division Sign-Off)

Division of Reproductive, Abdominal,

and Thoracic Devices

510(k) Number K053154

Transducer: CA621

Clinical Application	Mode of Operation									
	A	B	M	PWD	CWD	Color Doppler	Amplitude Doppler	Color Velocity Imaging	Combined (specify)	Other (specify)
Ophthalmic										
Fetal		N	N	N		N	N		N[1]	N[2], N[3]
Abdominal		N	N	N		N	N		N[1]	N[2], N[3]
Intraoperative (specify)										
Intraoperative Neurological										
Pediatric		N	N	N		N	N		N[1]	N[2], N[3]
Small Organ (specify)										
Neonatal Cephalic										
Adult Cephalic										
Cardiac										
Transesophageal										
Transrectal										
Transvaginal										
Transurethral										
Intravascular										
Peripheral Vascular										
Laparoscopic										
Musculo-skeletal Conventional										
Musculo-skeletal Superficial										
Other (specify)										

N=new indication; P=previously cleared by FDA; E= added under Appendix E

Additional Comments:

- [1] Applicable combined modes: B+M+PW+CFM+Amplitude Doppler.
- [2] Tissue Enhancement Imaging (TEI)
- [3] 3D Imaging

*Nancy Brogdon*  
 (Division Sign-Off)  
 Division of Reproductive, Abdominal,  
 and Radiological Devices  
 510(k) Number K053154

Transducer: BC432P

[illegible]

N=new indication; P=previously cleared by FDA; E= added under Appendix E

Additional Comments:

- Additional Comments:
- [1] Applicable combined modes: B+M+PW+CFM+Amplitude Doppler.
  - [2] Tissue Enhancement Imaging (TEI)
  - [3] 3D Imaging
  - [4] 4D Imaging

*Nancy C Brogdon*  
(District Office)  
Director, Reproductive, Abdominal,  
and Pelvic Diagnostic Devices  
K053154

Transducer: EC123

Clinical Application	Mode of Operation									
	A	B	M	PWD	CWD	Color Doppler	Amplitude Doppler	Color Velocity Imaging	Combined (specify)	Other (specify)
Ophthalmic										
Fetal										
Abdominal										
Intraoperative (specify)										
Intraoperative Neurological										
Pediatric										
Small Organ (specify)										
Neonatal Cephalic										
Adult Cephalic										
Cardiac										
Transesophageal										
Transrectal		P	P	P		P	P		P[1]	P[2], N[3]
Transvaginal		P	P	P		P	P		P[1]	P[2], N[3]
Transurethral										
Intravascular										
Peripheral Vascular										
Laparoscopic										
Musculo-skeletal										
Conventional										
Musculoskeletal Superficial										
Other (specify)										

N=new indication; P=previously cleared by FDA; E= added under Appendix E

Additional Comments:

[1] Applicable combined modes: B+M+PW+CFM+Amplitude Doppler.

[2] Tissue Enhancement Imaging (TEI)

[3] 3D Imaging

*Nancy C. Brogdon*  
 (Division Site) *EC123*  
 Division of Reproductive, Abdominal,  
 and Radiological Devices  
 510(k) Number *K053154*

Transducer: E8-5 R10

Clinical Application	Mode of Operation									
	A	B	M	PWD	CWD	Color Doppler	Amplitude Doppler	Color Velocity Imaging	Combined (specify)	Other (specify)
Ophthalmic										
Fetal										
Abdominal										
Intraoperative (specify)										
Intraoperative Neurological										
Pediatric										
Small Organ (specify)										
Neonatal Cephalic										
Adult Cephalic										
Cardiac										
Transesophageal										
Transrectal		P	P	P		P	P		P[1]	P[2], N[3]
Transvaginal		P	P	P		P	P		P[1]	P[2], N[3]
Transurethral										
Intravascular										
Peripheral Vascular										
Laparoscopic										
Musculo-skeletal										
Conventional										
Musculoskeletal Superficial										
Other (specify)										

N=new indication; P=previously cleared by FDA; E= added under Appendix E

Additional Comments:

[1] Applicable combined modes: B+M+PW+CFM+Amplitude Doppler.

[2] Tissue Enhancement Imaging (TEI)

[3] 3D Imaging

*Nancy C Brogdon*  
 (Division Sign Off)  
 Division of Reproductive, Abdominal,  
 and Radiological Devices  
 510(k) Number K053154